Vascularization, especially organ-level vascularization, has been a long-standing challenge in the field of tissue engineering since the beginning of the field. Here we analyze recent advances in the techniques aimed at vascularizing entire organs. Particularly recent advances in the use of projection stereolithography and food colors as photoabsorbers to create intricate networks and various complex organ-level tissue architectures in hydrogel are highlighted. We also reflected on several recent studies in the clinical translation of engineered vasculature. We find that the future is indeed bright for organ-level vascularization. However, future work is needed to determine the ability of direct vascular anastomosis, as well as long term patency and stability of these engineered structures.
Introduction
Engineering large-scale functional tissues and organs for tissue repair or organ replacement has always been the ultimate goal of tissue engineering and regenerative medicine. This grand challenge, which is as old as the field itself, is so complex and daunting that it is fair to view it as the Mars Mission in bioengineering. Even though there are numerous challenges and hurdles that we have to overcome in this process, the problem is still worth solving as the clinical issue of organ-shortage and end-stage diseases will not go away. The move towards a solution is inevitable and will fundamentally expand the arsenal of modern medicine from the use of drugs to the use of engineered tissues. As with any great strides in science, in the process of tackling this grand challenge in tissue engineering, the advances we have seen over the years are already benefiting and opening up new fields, such as organ-on-a-chip engineering, bio-robotics, drug delivery, etc.
Evolution of tissue vascularization and organ-level vascularization
At the heart of this problem of constructing large functional tissues or organs is tissue vascularization, which is relevant for all organ systems, but especially in cardiac tissue engineering. The high metabolic rate of cardiomyocytes is reflected by the capillary density in the heart: almost every cardiomyocyte neighbors a capillary to facilitate efficient mass transfer 1 . Establishing functional perfusable vasculature is a fundamental challenge we need to overcome for both the long-term goal of building an entire transplantable organ in the lab and the medium-term goal of repairing large tissue defects by implanting engineered tissues. Initial vascularization solutions stemmed from biological methods (i.e., growth factor delivery, gene therapy, cell therapy, etc.) that attempted to stimulate endogenous blood vessel growth into the infarcted myocardium, reducing the expansion of the infarct and improving heart function 2 . But these approaches that seek to improve vascular supply in pre-existing organs with vascular insufficiency have met with limited success. For example, the delivery of angiogenic growth factors such as vascular endothelial growth factor (VEGF) by protein or gene therapy can result in vasculature that is highly disorganized and leaky 3 . This approach is further limited by complex pharmacokinetics, the high cost to maintain growth factor levels, the requirement for localized effects and low in vivo transfection rates in gene therapy 4 . A relatively new branch of research focuses on manipulating endogenous non-coding RNAs (~22 nucleotides), known as microRNAs, to direct myocardial angiogenesis, the early results of which are promising 5 . However, it seems unlikely that endogenous endothelial repair alone can regenerate an injury as large as a major myocardial infarct 6 . The natural development of vasculature and tissue takes place at a time and physical scale that is too slow and too small to satisfy the level of therapeutic support that clinicians seeks in dealing with large tissue defects and end-stage disease. Therefore, there is a need to engineer functional tissues in vitro prior to implantation to repair large tissue defects. However, engineered thick tissue construct cannot be viably maintained in the lab or in vivo unless there is perfused vasculature, which is also difficult to establish with the use of growth factor alone. This challenge leads to the value proposition of tissue engineering, which seeks to deliver a therapeutic alternative with engineering methods to overcome this limitation.
Engineering strategies to accelerate vascularization include the direct fabrication of branching templates on which endothelial cells can assemble in vitro. Borenstein et al. first fabricated vascular network templates by silicon etching using polydimethylsiloxane (PDMS) molding 7,8 . However, materials such as PDMS are non-biodegradable and thus have limited usefulness in vivo. Since then, the field has shifted to the use of biocompatible and biodegradable materials such as poly(lactide-co-glycolide) (PLG) and poly(glycerol sebacate) (PGS). The mechanical strength and the biodegradable properties of PGS allow it to be molded into a vascular network using standard soft lithography techniques 9 . A subtractive method is often used, where a sacrificial vascular network is first created from gelatin 10,11 and then embedded within a cellladen hydrogel. The gelatin structures are subsequently removed by increasing the temperature of the construct to physiological conditions, leaving behind open channels for endothelialization. Later on, mechanically stable carbohydrate glass or Pluronic acid, which can be printed with a 3D printer, were used to replace gelatin as the sacrificial material, which greatly facilitated the scaling of this subtractive fabrication method 12 . However, creating complex biological structures by printing the sacrificial material in mid-air is still challenging. Nonetheless, this is a popular technique, especially in fabricating micro-physiological models.
More recently, rapid advances in hydrogel fabrication have been made to unlock the design freedom in organ engineering. Jordan Miller and colleagues recently demonstrated in Science the 3D printing of ultra-complex organ-level intravascular and multivascular systems in photopolymerizable hydrogel with projection stereolithography (Figure 1 a) 13 . Specifically, perfusable 3D networks resembling a vascularized lung alveolar sac was printed and then perfused with blood, which interestingly revealed that the redirection of blood flow and intravascular mixing induced by alveolar inflation may have improved the rate of oxygen exchange (Figure 1b) . This observation points to tangible organ-level functional improvements as a result of recapitulating organ-level biological architectures. Impressively, Miller and colleagues were able to create complex curved shapes, entangled vascular networks and shapes identical to 3D bicuspid valves, using the simplest materials: photocrosslinkable polyethylene glycol and commercial food dyes that served as photoabsorber additives for projection stereolithography. Their study is unprecedented in terms of both resolution and complexity of the created shapes. The team also demonstrated that implantation of vascularized liver tissue created by this approach is possible. In the future, if integrated with 3D organoid culture, unprecedented biological complexity and scale could be simultaneously established.
Another approach of creating complex 3D organ-level structures is based on freeform reversible embedding of suspended hydrogels (FRESH) 14 . Printing biomaterial in mid-air has always been a major challenge, especially for slow-gelling materials. To overcome this issue, the FRESH technique allows biological materials to be printed in a bath of viscous gel which can serve as a temporary, thermoreversible, and biocompatible support. This approach opens up the possibility of directly printing natural hydrogels, such as collagen, fibrin, Matrigel TM , or even decellularized matrices into complex 3D structures. Recently, as a proof-of-concept study, the technique was used to print cell-laden decellularized hydrogels into the anatomical structure of an entire heart including the heart chambers and the major coronary vessels. Although tissue function is yet to be demonstrated at this organ-scale construct, the high level of structural complexity of the 3D printed natural biomaterial achieved is a major advance.
Undoubtedly, much progress has been made since the first publication of microfluidic soft hydrogel with the conventional microfabrication techniques in 2007 15 . Today there is no shortage of engineering methods to construct complex 3D hydrogel structures. However, being able to precisely pattern cells and lay down complex organ-level architecture, although important, is only the first step of a long journey to establishing tissue or organ functions at the therapeutic level. The major shortcomings of the 3D printing hydrogel-based methods are the inability to simultaneously reach physiological cell density within the gel while preserving the engineered vasculature as well as the inability to easily apply this architecture in vivo, especially in high pressure environments. Properties such as burst strength and suture retention strength are generally inferior in hydrogels, compared to the polymers used to construct commonly used vascular grafts.
Tissue remodeling is a crucial step in achieving high physiological cell density and tissue maturation. Because the dynamic nature of the tissue remodeling process, there is a need to guide tissue growth at multiple length and time scales, which could potentially be coordinated by the choice of biomaterials or combination of multiples biomaterials. Multi-material extrusion-based printing of vascularized cartilage tissues was demonstrated, which showed tissue remodeling and differentiation can be supported in large tissue constructs with multimaterial based 3D printing approach 16 . However, multi-material printing of complex perfusable vascular structure is yet to be demonstrated and might be necessary to further elevate biological functionality and structural stability of printed tissues.
To date, the entire tissue engineering field is mainly rooted in enhancing the precision of scaffold and hydrogel fabrication, where the material still functions mainly as static structural support and lacks dynamic functionalities. Appreciating the complex and dynamic nature of human tissues, this field might require innovative tissue assembly strategies that do not merely view a scaffold as a static skeleton, but a dynamic machine that guides tissue assembly over time. Recognizing this fourth dimension in bio-fabrication could transform the way we approach tissue and organ engineering. For instance, 4D printing and origami tissues are emerging developments that combine 3D printing or micropatterning with smart functional biomaterials that can change shape over time, based on their intrinsic properties or external stimulation 17 . Although the technique is more widely used in developing soft-robotics, sensors, and actuators, etc. novel tissue engineering solutions based on this concept are still emerging.
Clinical translation of engineered vasculature
As challenging as engineering organ-level vasculature, establishing rapid vascular integration and maturation in vivo is crucial in maintaining the viability and growth of the implanted vessels and tissues post-transplantation. By simply incorporating endothelial cells in an engineered tissue implant, blood vessels can naturally form in vivo from the self-assembly of the implanted endothelial cells, but vascular perfusion will take 1-2 weeks to establish 18 . During this period, implanted parenchymal cells, such as cardiomyocytes, will die within 1-2 days post implantation without the supply of oxygen and nutrients from vascular perfusion. The vascularization process is slow because the randomly distributed endothelial cells have to come together to assemble into mature vasculature. By pre-organizing the endothelial cells in vitro into an array of linear vessels in parallel, the time to achieve vascular perfusion in vivo post-transplantation can be significantly reduced to just 3-5 days (Figure 1 c,d) 19, 20 . When the engineered vasculature is accompanied by parenchymal cells, such as hepatocytes or pancreatic islets that are highly susceptible to apoptosis due to insufficient oxygen and nutrient diffusion, the resulting accelerated vascularization led to significant functional and therapeutic improvements in vivo 20 .
Long-term vascular maturation and the prevention of vascular regression are also key issues to consider. Although blood vessels resulting from primary human endothelial cells alone, were demonstrated to be capable of rapid vascular integration, their long-term vascular maturation will require the participation of relevant stromal cells. Furthermore, the formation of the vascular hierarchy will require the differentiation of arterial and venous phenotypes. These issues could potentially be addressed by taking advantage of the phenotypic plasticity of induced pluripotent stem cells (iPSC) derived endothelial progenitor cells. IPSC-derived human blood vessel organoids have been shown to contain both endothelial cells and pericytes that can self-assemble into functional and matured capillary networks (Figure 1 e) 21 . When transplanted, the blood vessel organoids form stable, perfused vascular trees, including arteries, arterioles, and venules, in mice (Figure 1 f) . The system can also be used to model diseases such as diabetic vasculopathy that is manifested by the thickening of the vascular basement membrane, which now can be directly observed in the organoid culture in vitro. It is also important to emphasize that the use of iPSC as a cell source will not only lead to personalized drug discovery, but also result in significantly improved biocompatibility and immunocompatibility when transplanted.
The reciprocating interaction of the vasculature and the parenchymal tissues, which are often developed and matured concurrently, also play a vital role in the organ development process. Tissue organoids produced by the tri-culture of iPSC-derived hepatocytes with primary endothelial cells and mesenchymal stem cells were shown to not only improve in vivo vascularization, but the resulting vasculature can also help stimulate the maturation of iPSChepatocytes into matured tissues resembling the adult liver 22 . This same strategy has also been shown to be applicable to a variety of organ systems 23 . Furthermore, taking advantage of the plasticity of iPSC-derived endothelial cells, the co-culture of these endothelial cells with parenchymal cells could potentially induce organ-specific vascular differentiation, which should be explored in the future 24 . Pre-organized vasculature supported with parenchymal tissues and sourced from iPSCs or organoids can clearly provide in vivo vascularization and has already presented sufficient evidence of efficacy in small animals. Translation to large animals is potentially feasible but is yet to be determined. The challenge of vascularization strategies that relies on native angiogenesis and vascular integration is that the rate of vascularization and vascular maturation could drastically change in clinical translation due to the decrease in surface-to-volume ratio of the tissue implant as well as in the rate of vascular growth in humans, especially older adults. Therefore, it remains to be seen if prior success in small animals is translatable to human trials.
Establishing direct surgical vascular connection is feasible and could overcome this reliance on the rate of natural vascular integration. We reported the fabrication of a biodegradable scaffold (commonly referred to as AngioChip) that contains a perfusable, branched, three-dimensional microchannel network coated with endothelial cells to mimic the human vascular networks 25 . The permeability of the network was improved without compromising mechanical stability by incorporating nanopores and micro-holes in the vessels walls, which also permits the intercellular crosstalk and extravasation of monocytes and endothelial cells on biomolecular stimulation. Surrounding the vasculature, a variety of parenchymal cells can be cultured. We showed our engineered vascularized hepatic tissue can metabolize drugs delivered through the internal vasculature and our engineered vascularized cardiac muscles can achieve high physiological cell density and contract macroscopically without collapsing the internal networks. Lastly, we demonstrated direct surgical vascular anastomosis of our engineered tissue to the femoral vessels of rat hindlimbs, hence establishing immediate blood perfusion after surgical implantation (Figure 1 g,h) . However, current limitation relies on the scalability of the synthetic scaffolds. Furthermore, to engineer organ-level vasculature with surgical vascular connections, engineered branching vasculature will need to be more consistently assessed from standard properties that are used to assess the functionality of vascular grafts, including burst pressure, suture retention strength, platelet adhesion, complement activation, thrombogenicity and longterm patency in vivo. Ultimately, the viability of the tissue implants will rely on sustained vascular perfusion, which is especially crucial in the early days post-implantation.
Future perspectives
Considering both engineering complexity and translational efficacy, it's clear that designing a functional tissue or an organ will require the right balance between tissue self-assembly and engineered design. This balance relies on advances in our bioengineering capabilities and our understanding of cell biology (Figure 2) . Often it appears that there are so many techniques one can choose from and yet few of these methods can provide the complete tissue engineering solution that can check all the requirements. However, advances in bioengineering, even if they offer an incomplete solution, often lead to a deeper understanding of cell biology. A more indepth comprehension in cell biology will, in turn, guide the development of the next generation of engineering strategies. Meanwhile, to benefit from the current development in bioengineering, it's important to first acquire an understanding of the required level of tissue functionality, structural complexity, and material compatibility. Only then the clinical application can be tailored to the most appropriate engineering technique.
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